Dieter Schrenk mostly deals with Biochemistry, Pharmacology, Multidrug resistance-associated protein 2, Aryl hydrocarbon receptor and World health. His Metabolite, Organic anion transport and Mutation study in the realm of Biochemistry connects with subjects such as Conjugated system. His Pharmacology study combines topics from a wide range of disciplines, such as Cell culture and P-glycoprotein.
His Aryl hydrocarbon receptor research incorporates elements of Cancer research, Stereochemistry, Cytochrome P450 and Enzyme inducer. Throughout his World health studies, Dieter Schrenk incorporates elements of other sciences such as Polychlorinated dibenzodioxins, Environmental health, Polybrominated Biphenyls and Environmental chemistry. His Polybrominated Biphenyls research incorporates themes from Dioxins and dioxin-like compounds and Polychlorinated naphthalene.
Dieter Schrenk focuses on Biochemistry, Toxicity, Pharmacology, Carcinogen and Internal medicine. His research in Toxicity intersects with topics in Environmental chemistry and In vitro. His study in Environmental chemistry focuses on Polychlorinated dibenzofurans in particular.
His Carcinogen research is multidisciplinary, relying on both Mode of action and Genotoxicity. Dieter Schrenk works mostly in the field of Internal medicine, limiting it down to topics relating to Endocrinology and, in certain cases, Tumor promotion and Hepatocyte. His study looks at the relationship between Cytochrome P450 and fields such as Aryl hydrocarbon receptor, as well as how they intersect with chemical problems.
Dieter Schrenk mainly focuses on Toxicity, Pyrrolizidine, Carcinogen, Toxicology and Biochemistry. The various areas that Dieter Schrenk examines in his Toxicity study include Incidence, Environmental health, Adult age, European population and Physiology. His studies deal with areas such as Young age, Tolerable daily intake and Honey Bees as well as Environmental health.
His Pyrrolizidine research includes themes of Glutathione, Genotoxicity, Cytotoxicity, Traditional medicine and Pharmacology. In his works, Dieter Schrenk conducts interdisciplinary research on Toxicology and Quinolizidine. His Microsome, Metabolism and Cytochrome P450 study are his primary interests in Biochemistry.
His main research concerns Toxicology, Genotoxicity, Body weight, Toxicokinetics and Toxicity. His study deals with a combination of Toxicology and Quinolizidine. Dieter Schrenk has researched Genotoxicity in several fields, including Chromatography, Fraction and Toxicity aspects.
His study in Body weight is interdisciplinary in nature, drawing from both Adult age, European population, Animal science and Human study. His Toxicokinetics study is focused on Pharmacology in general. His research integrates issues of Glyphosate, Adverse effect, Physiology and Genetically modified organism in his study of Toxicity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds.
Martin Van den Berg;Linda S. Birnbaum;Michael Denison;Mike De Vito.
Toxicological Sciences (2006)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott.
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.
Markus Waldecker;Tanja Kautenburger;Heike Daumann;Cordula Busch.
Journal of Nutritional Biochemistry (2008)
Opinion of the Scientific Panel on Contaminants in the Food chain on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts
D. Benford;J. de Boer;A. Carere;A. di Domenico.
EFSA Journal (2008)
Dioxins: WHO’s tolerable daily intake (TDI) revisited
F.X.Rolaf van Leeuwen;Mark Feeley;Dieter Schrenk;John Christian Larsen.
Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction
Kristin Westphal;Anita Weinbrenner;Michael Zschiesche;Gerd Franke.
Clinical Pharmacology & Therapeutics (2000)
The effect of rifampin treatment on intestinal expression of human MRP transporters
Martin F. Fromm;Hans-Martin Kauffmann;Peter Fritz;Oliver Burk.
American Journal of Pathology (2000)
Bioactive compounds: definition and assessment of activity
Hans-Konrad Biesalski;Lars Ove Dragsted;Ibrahim Elmadfa;Rolf Grossklaus.
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Karl Bock;Dieter Schrenk;Adelheid Forster;Ernst-Ulrich Griese.
Gene and Protein Expression of P-Glycoprotein, MRP1, MRP2, and CYP3A4 in the Small and Large Human Intestine
Sofia Berggren;Christine Gall;Nadine Wollnitz;Mats Ekelund.
Molecular Pharmaceutics (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: